sporad
yet
frequent
human
infect
avian
influenza
virus
continu
pose
potenti
pandem
threat
poor
immunogen
unadjuv
vaccin
warrant
develop
novel
adjuv
formul
well
altern
deliveri
system
improv
immunogen
efficaci
show
protollin
nasal
adjuv
compos
neisseria
meningitid
outer
membran
protein
noncoval
link
shigella
flexneri
lipopolysaccharid
potent
nasal
adjuv
inactiv
split
virion
clade
aviet
vaccin
mous
model
protollinadjuv
vaccin
elicit
enhanc
serum
protect
hemagglutin
inhibit
titer
mucos
iga
respons
cellmedi
immun
result
complet
protect
lethal
challeng
homolog
viru
well
heterolog
clade
viru
detail
analysi
adapt
immun
reveal
protollin
increas
frequenc
lymphoida
well
local
tissueresid
antibodysecret
cell
local
germin
center
reaction
b
cell
broadspectrum
cell
respons
find
suggest
nasal
deliveri
vaccin
protollin
adjuv
overcom
poor
immunogen
vaccin
induc
cellular
humor
immun
respons
enhanc
protect
challeng
clade
clade
virus
achiev
signific
antigen
dosespar
world
alreadi
experienc
three
influenza
pandem
centuri
addit
recent
pandem
caus
swineorigin
viru
taught
us
newli
emerg
pathogen
risk
global
popul
highli
pathogen
avian
influenza
virus
continu
prime
candid
next
influenza
pandem
steadili
caus
fatal
infect
human
popul
far
direct
humantohuman
transmiss
appear
infrequ
howev
accumul
mutat
may
break
genet
barrier
gener
viru
transmiss
among
human
potenti
caus
pandem
inher
poor
immunogen
unadjuv
influenza
vaccin
warrant
effort
explor
novel
adjuv
altern
deliveri
system
improv
immunogen
protect
efficaci
vaccin
intraderm
id
oral
nasal
deliveri
vaccin
repres
altern
rout
convent
intramuscular
im
deliveri
unlik
im
id
rout
oral
nasal
deliveri
noninvas
needlefre
known
induc
mucos
system
immun
respons
sinc
degrad
antigen
proteolyt
enzym
poor
absorpt
need
larg
dose
antigen
concern
toler
still
remain
challeng
oral
deliveri
nonrepl
vaccin
antigen
nasal
rout
becom
attract
option
vaccin
particularli
respiratori
pathogen
respiratori
tract
equip
pathogen
sens
defens
mechan
larg
surfac
area
absorpt
highli
vascular
live
attenu
season
influenza
vaccin
deliv
intranas
laiv
flumist
fluenz
tm
medimmun
astrazenica
approv
healthi
individu
year
age
us
howev
absenc
correl
immun
coldstorag
requir
potenti
genet
recombin
season
influenza
virus
may
limit
use
laiv
prepandem
influenza
http
vaccin
therefor
ideal
vaccin
formulatedadjuv
nasal
deliveri
induc
mucos
well
system
serolog
cellular
immun
respons
correl
protect
protollin
nasal
adjuv
compos
neisseria
meningitidi
outer
membran
protein
omp
noncoval
complex
shigella
flexneri
lipopolysaccharid
lp
activ
innat
immun
system
via
activ
omp
lp
respect
protollin
shown
induc
effect
system
well
mucos
antibodi
respons
preclin
studi
administ
sever
viral
antigen
measl
sar
corona
viru
rsv
recombin
plagu
antigen
therefor
protollin
repres
attract
adjuv
suitabl
nasal
deliveri
prepandem
vaccin
studi
evalu
immunogen
protect
challeng
confer
protollinadjuv
inactiv
split
vaccin
monoval
influenza
split
vaccin
provid
glaxosmithklin
vaccin
stefoy
quebec
canada
protollin
gsk
vaccin
consist
proteosom
outer
membran
protein
deriv
wildtyp
neisseria
meningitidi
group
b
noncoval
complex
approxim
ratio
lipopolysaccharid
lp
isol
shigella
flexneri
serotyp
amount
protollin
express
lg
lp
amount
vaccin
express
lg
ha
two
viru
strain
made
revers
genet
engin
ha
na
clade
aviet
clade
remain
six
gene
segment
apuerto
virus
propag
old
embryon
chicken
egg
h
pool
allanto
fluid
clarifi
centrifug
aliquot
store
use
femal
balbc
mice
jackson
laboratori
bar
harbor
main
week
age
anesthet
intraperiton
inject
ip
tertamyl
alcohol
avertin
sigmaaldrich
st
loui
mo
nasal
inocul
mg
vaccin
either
alon
mg
protollin
final
volum
ml
administ
slowli
drop
drop
ml
per
nostril
vaccin
antigen
adjuv
mix
prior
immun
mice
nasal
administ
adjuv
alon
use
neg
control
four
week
later
mice
receiv
second
dose
vaccin
prepar
one
week
boost
mice
euthan
collect
spleen
bone
marrow
tissu
assess
adapt
immun
bronchoalveolar
lavag
bal
nasal
lavag
also
perform
time
inject
ml
pb
proteas
inhibitor
recollect
fluid
measur
mucos
antibodi
respons
elisa
mice
bled
week
postprimari
week
postboost
measur
hemagglutin
inhibit
hi
titer
use
hors
red
blood
cell
four
week
boost
mice
group
challeng
ld
virus
anim
monitor
daili
morbid
chang
bodi
weight
mous
lost
preinfect
bodi
weight
euthan
anim
research
conduct
guidanc
cdc
institut
anim
care
use
committe
statist
analysi
perform
use
graphpad
prism
softwar
graphpad
softwar
la
jolla
ca
student
test
use
analyz
differ
antibodi
isotyp
two
group
oneway
analysi
varianc
bonferroni
post
analysi
use
analyz
differ
among
treatment
mannwhitney
test
use
determin
signific
among
hi
titer
final
logrank
mantelcox
test
use
compar
percent
surviv
among
group
mice
differ
consid
statist
signific
pvalu
investig
adjuv
effect
protollin
mice
nasal
administ
mg
vaccin
without
mg
protollin
use
primeboost
regim
challeng
homolog
virus
mice
immun
mg
vaccin
alon
succumb
challeng
day
postchalleng
mice
receiv
highest
dose
vaccin
mg
initi
show
signific
weight
loss
eventu
surviv
challeng
fig
b
mice
immun
vaccin
plu
protollin
includ
mice
receiv
lowest
vaccin
antigen
dose
mg
surviv
signific
weight
loss
observ
fig
b
data
demonstr
protollin
significantli
enhanc
protect
efficaci
vaccin
test
whether
protollinmedi
protect
extend
crossclad
viru
vaccineimmun
mice
challeng
clade
viru
mice
immun
either
protollin
vaccin
alon
mg
succumb
challeng
fig
among
mice
immun
mg
vaccin
alon
mice
show
weight
loss
eventu
recov
surviv
howev
protollinadjuv
vaccin
even
lowest
vaccin
dose
mg
significantli
reduc
weight
loss
complet
protect
mice
lethal
challeng
fig
therefor
protollin
also
enhanc
crossclad
protect
signific
antigen
dosespar
next
assess
whether
improv
protect
confer
protollinadjuv
vaccin
due
enhanc
antibodi
titer
mice
immun
describ
fig
sera
collect
week
follow
primari
immun
week
booster
immun
week
measur
hi
titer
homolog
viru
well
heterolog
viru
mice
immun
unadjuv
vaccin
induc
detect
antibodi
titer
follow
primari
immun
howev
mice
immun
protollin
adjuv
vaccin
mg
ha
develop
low
level
antibodi
titer
even
singl
vaccin
data
shown
week
mice
immun
vaccin
plu
protollin
develop
significantli
higher
level
hi
titer
homologu
heterolog
virus
fig
c
howev
none
mice
immun
vaccin
alon
detect
hi
titer
viru
fig
mice
immun
either
mg
ha
unadjuv
vaccin
develop
detect
hi
titer
viru
fig
furthermor
vaccin
alon
elicit
product
wherea
protollin
adjuvant
induc
mix
respons
clear
trend
toward
h
respons
fig
result
indic
protollin
significantli
enhanc
immunogen
vaccin
skew
immun
respons
toward
h
respons
determin
whether
protollin
increas
frequenc
agspecif
memori
b
cell
mice
immun
describ
fig
frequenc
antibodysecret
cell
asc
spleen
bone
marrow
examin
elispot
assay
shown
fig
b
frequenc
igg
igm
asc
spleen
increas
mice
immun
unadjuv
vaccin
protollin
significantli
increas
frequenc
igg
igm
asc
even
lowest
dose
mg
although
agspecif
igm
asc
frequenc
much
lower
agspecif
igg
asc
bone
marrow
frequenc
igg
asc
similarli
enhanc
use
protollin
adjuv
frequenc
igm
asc
minim
affect
protollin
fig
togeth
data
suggest
intranas
administr
vaccin
protollin
enhanc
overal
frequenc
asc
signific
dosespar
effect
next
activ
vaccinespecif
cell
spleen
assess
mice
immun
mg
vaccin
without
protollin
cell
product
ifnc
detect
mice
immun
unadjuv
vaccin
compar
protollin
control
group
protollin
adjuvant
increas
ifnc
product
significantli
fig
hand
tnfa
product
activ
cell
compar
protollin
alon
vs
vaccin
group
howev
coadministr
protollin
vaccin
significantli
increas
tnfa
product
cell
vaccinespecif
cell
respons
slightli
increas
upon
protollin
adjuvant
increas
statist
signific
data
shown
summari
data
suggest
protollinadjuv
vaccin
enhanc
broad
spectrum
cell
activ
pathway
h
ifnc
tnfa
h
h
system
increas
asc
frequenc
protollin
prompt
us
assess
extent
home
asc
back
local
immun
induct
site
thu
measur
iga
elisa
week
follow
booster
immun
fluid
bronchoalveolar
bal
nasal
lavag
mice
immun
previous
describ
fig
iga
secret
unadjuv
vaccin
antigenimmun
mice
bare
detect
nasal
lavag
fig
bal
fig
contrast
mice
immun
vaccin
antigen
plu
protollin
produc
iga
minimum
higher
mice
immun
unadjuv
vaccin
addit
protollin
significantli
enhanc
clade
iga
secret
nasal
bal
compar
vaccin
alon
fig
secret
igg
antibodi
also
greatli
enhanc
protollin
reactiv
extend
clade
viru
fig
howev
frequenc
igm
asc
much
lower
minim
affect
protollin
fig
data
indic
nasal
administr
protollinadjuv
vaccin
enhanc
local
mucos
immun
throughout
respiratori
tract
next
activ
statu
b
cell
peak
primari
respons
day
assess
flow
cytometr
analysi
com
pare
mice
immun
vaccin
alon
mice
immun
vaccin
plu
protollin
higher
frequenc
b
cell
particip
gc
reaction
fig
higher
overal
mean
fluoresc
intens
among
gcparticip
b
cell
gcb
cell
express
high
level
fig
plasma
cell
differenti
low
level
reveal
differ
among
group
fig
interestingli
protollin
alon
recruit
b
cell
gc
reaction
induc
activ
fig
emphas
signific
role
innat
signal
b
cell
activ
nonetheless
recruit
gc
reaction
activ
result
product
agspecif
antibodi
fig
also
measur
frequenc
splenic
agspecif
igg
igm
primari
respons
found
protollin
adjuvant
significantli
increas
earli
igg
secret
margin
igm
secret
fig
f
overal
data
suggest
protollin
recruit
b
cell
earli
phase
vaccin
respons
spread
evolut
highli
pathogen
influenza
viru
bird
worldwid
increas
number
case
direct
transmiss
human
lead
fatal
rais
concern
immin
influenza
pandem
vaccin
unquestion
one
costeffect
public
health
intervent
avail
protect
pandem
howev
current
avail
unadjuv
vaccin
administ
im
rout
poorli
immunogen
new
strategi
improv
immunogen
vaccin
adjuv
novel
formul
altern
deliveri
methodolog
meet
demand
global
popul
still
urgent
need
current
studi
evalu
use
protollinadjuv
vaccin
nasal
deliv
prepandem
vaccin
mous
model
mucos
immun
system
respiratori
track
play
import
role
prevent
influenza
viru
infect
upper
respiratori
tract
equip
physic
dynam
barrier
mucu
well
solubl
membran
bound
pathogen
sensor
also
contain
nasopharyngealassoci
lymphoid
tissu
nalt
enrich
agspecif
mucos
effector
cell
well
innat
immun
cell
henc
nasal
deliveri
antigen
trigger
local
mucos
well
system
immun
respons
crucial
respiratori
pathogen
includ
influenza
nasal
deliveri
split
inactiv
influenza
vaccin
gener
requir
mucos
adjuv
induc
strong
protect
immun
respons
mucos
adjuv
contain
bacteri
toxin
deriv
includ
esherichia
coli
heat
labil
enterotoxin
lt
clinic
eval
data
repres
independ
experi
mice
per
group
error
bar
repres
standard
error
mean
sem
oneway
analysi
varianc
bonferroni
post
analysi
use
analyz
differ
among
treatment
student
test
use
analyz
differ
antibodi
isotyp
two
group
uat
subunit
influenza
vaccin
ultim
licens
europ
soon
withdrawn
market
due
increas
incid
bell
palsi
postvaccin
clinic
trial
proteosomeadjuv
either
monoval
trival
inactiv
vaccin
shown
proteosomeadjuv
vaccin
welltoler
induc
significantli
higher
serum
hi
mucos
secretori
iga
titer
compar
unadjuv
vaccin
preclin
studi
use
protollinadjuv
vaccin
also
show
similar
result
consist
data
show
protollinadjuv
vaccin
induc
significantli
higher
level
mucos
iga
antibodi
viru
nasal
wash
lung
consider
dosespar
effect
breadth
mucos
iga
respons
extend
clade
viru
prepandem
vaccin
formul
crossclad
immun
import
desir
featur
current
endem
virus
continu
evolv
ha
antigen
antigen
drift
reassort
thu
make
hard
predict
strain
caus
pandem
protollin
also
induc
crossreact
igg
well
low
yet
detect
level
igm
antibodi
lungresid
memori
b
cell
well
mucos
secretori
iga
andor
igg
antibodi
play
crucial
role
confer
protect
influenza
viru
challeng
mice
immun
protollinadjuv
vaccin
complet
protect
lethal
challeng
clade
clade
virus
therefor
protollinadjuv
repres
novel
prepandem
vaccin
candid
effici
induc
protect
mucos
system
immun
adjuv
properti
protollin
document
conjunct
antigen
variou
infecti
agent
includ
measl
recombin
sarsspik
glycoprotein
respiratori
syncyti
viru
rsv
recombin
plagu
antigen
level
serum
igg
respons
induc
protollin
gener
compar
alumadjuv
vaccin
show
mix
h
h
respons
h
trend
higher
ratio
compar
unadjuv
vaccin
consist
find
data
demonstr
protollin
potenti
immunogen
vaccin
singl
vaccin
mice
immun
protollin
adjuv
vaccin
mg
develop
detect
level
serum
hi
titer
follow
booster
immun
protollin
adjuv
vaccin
significantli
increas
serum
hi
titer
compar
unadjuv
vaccin
coincid
complet
protect
homolog
viru
challeng
breadth
antibodi
respons
also
broaden
protollinadjuv
vaccin
significantli
increas
serum
hi
titer
viru
compar
vaccin
alon
group
fulli
protect
mice
viru
challeng
protect
influenza
viru
infect
includ
antibodymedi
neutralizationblock
viru
cellmedi
clearanc
virusinfect
cell
although
antigenspecif
cell
respons
significantli
enhanc
protollin
adjuvant
data
shown
protollinadjuv
vaccin
significantli
increas
product
cytokin
antigenspecif
cell
h
ifnc
tnfa
h
h
ifnc
repres
cytokin
h
respons
promot
overal
microbi
kill
enhanc
phagocytosi
recruit
mononuclear
cell
site
infect
favor
product
b
cell
hand
along
shape
h
respons
promot
product
isotyp
consist
cytokin
profil
mice
immun
protollinadjuv
vaccin
show
mix
respons
higher
product
typic
associ
pathogenesi
inflammatori
diseas
howev
protect
role
surviv
high
dose
challeng
sever
case
recent
demonstr
interest
note
protollinadjuv
vaccin
elicit
sharp
increas
product
compar
vaccin
alon
antiinflammatori
cytokin
produc
natur
regulatori
cell
treg
well
antigenspecif
effector
cell
remain
unclear
sourc
studi
regardless
enhanc
product
indic
fine
balanc
effector
vs
control
mechan
achiev
protollin
use
gene
knockout
mice
shown
critic
antigenspecif
antibodi
respons
protollinadjuv
rsv
vaccin
requir
elicit
balanc
h
h
immun
respons
although
requir
nanoparticl
format
play
role
adjuvant
protollin
summari
protollin
demonstr
signific
antigen
dosespar
effect
protollinadjuvant
vaccin
antigen
lower
dose
elicit
higher
serum
hi
titer
mucos
antibodi
respons
highest
vaccin
antigen
dose
mg
hamous
clade
clade
virus
enhanc
immun
respons
culmin
enhanc
protect
challeng
lethal
dose
virus
either
clade
clade
therefor
nasal
deliveri
protollinadjuv
vaccin
promis
approach
merit
develop
prepar
pandem
find
conclus
report
author
necessarili
repres
view
center
diseas
control
prevent
fund
agenc
wc
jk
ss
design
experi
interpret
data
wc
jk
ar
mh
vivo
experi
jb
challeng
experi
xl
hi
assay
wc
jk
ss
wrote
manuscript
sg
jk
mp
db
edit
manuscript
dsb
mp
employe
gsk
group
compani
time
studi
stock
option
gsk
list
inventor
patent
own
gsk
group
compani
remain
author
declar
commerci
financi
conflict
interest
work
support
influenza
divis
center
diseas
control
prevent
protollin
increas
earli
b
cell
respons
local
lymph
node
spleen
balbc
mice
micegroup
nasal
administ
mg
ha
split
virion
vaccin
antigen
without
mg
protollin
protollin
alon
control
week
later
mediastin
lymph
node
andor
spleen
collect
b
cell
stain
lymph
node
analyz
percentag
gcparticip
b
cell
plasma
cell
b
mean
fluoresc
intens
mfi
c
well
b
cell
express
high
among
gcparticip
b
cell
spleen
harvest
frequenc
igg
asc
e
igm
asc
f
measur
elispot
assay
number
igg
igm
asc
normal
number
total
igg
igm
secret
asc
present
agspecif
igg
igm
b
cell
data
repres
least
independ
experi
mice
group
error
bar
repres
standard
error
mean
sem
oneway
analysi
varianc
bonferroni
post
analysi
use
analyz
differ
among
treatment
